Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MetaSight Diagnostics has developed a proprietary high-throughput mass spectrometry-based platform that integrates large-scale serum sample analysis with deidentified electronic health records to discover robust disease signatures. Their first two products—tests for liver fibrosis/MASH and colorectal cancer—have completed comprehensive validation in multiple external cohorts and are being prepared for FDA clinical studies. The company claims significant advantages over existing tests in terms of cost-effectiveness, scalability, and accuracy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MetaSight Diagnostics.